Strategies for Osteoporosis Care-Section 3

Video Transcription

Video Summary

The speaker outlines an algorithm for osteoporosis management based on fracture risk, treatment response, and medication sequencing. For low-to-moderate risk patients without prior fragility fracture, oral or IV bisphosphonates or denosumab may be used, with yearly clinical review of adherence, side effects, calcium/vitamin D use, exercise, and cost barriers. If bone density is stable and no fractures occur, a bisphosphonate holiday may be considered after 5 years of oral therapy or 3 years of IV therapy. Worsening bone density or fractures prompts reassessment for secondary causes and possible escalation to more potent therapy.<br /><br />For high-risk patients, especially those with recent fragility fracture, anabolic therapy first (teriparatide, abaloparatide, romosozumab) is preferred, followed by an antiresorptive such as denosumab or zoledronic acid. Monitoring includes DXA every 1–2 years, sometimes bone turnover markers. Lifestyle advice includes smoking cessation, moderating alcohol, fall prevention, exercise, and adequate calcium and vitamin D.

Asset Subtitle

Bridging the Gap: Comprehensive Osteoporosis Care in Primary Practice

Meta Tag

Concept Osteoporosis

Concept Fracture Risk

Concept Pharmacotherapy

Concept Fragility Fracture

Concept Bone Density

Keywords

osteoporosis management

fracture risk

bisphosphonates

anabolic therapy

DXA monitoring

Osteoporosis

Fracture Risk

Pharmacotherapy

Fragility Fracture

Bone Density